Ohm comment: "...66.6% aren't. What we need to know is how many of those 66.6% were also using PD-1 inhibitors. If it was only those 5 or there were only a couple of the 66.6% that were then it would trend towards a leronlimab/ PD-1 inhibitor combo being a winner. It may be something as simple as every one of the 17 being on 525mg or 700mg and those 5 having less disease severity or genetics that respond better to leronlimab. That's why I like to have data it's the only way to parse out what's going on.

Is the data you prefer re: 66% available via research? CYDY? I'd like to believe the data has been collected - somewhere.

Nonetheless, I see only upside in the data as presented. Ambiguity? Yes, but no downside or hidden or damaging LL data weakness. Am I wrong to see only upside in the data? TIA.